Press Releases May 4, 2026 08:52 AM

Quantum X Labs Files U.S. Patent Application for High Precision Quantum Atomic Clock for Potential Use in the Aerospace & Defense Industries

Quantum X Labs Files Patent Application for High Precision Quantum Atomic Clock Targeting Aerospace & Defense Sectors

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
QXL

Quantum X Labs Inc. has filed a U.S. patent application covering a novel compact atomic clock utilizing advanced quantum technology to enhance precision. This innovation aims to deliver laboratory-grade performance in deployable, commercial-ready solutions for aerospace, defense, financial institutions, and critical infrastructure requiring high-precision timing.

Quantum X Labs Files U.S. Patent Application for High Precision Quantum Atomic Clock for Potential Use in the Aerospace & Defense Industries
QXL
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Quantum X Labs filed a U.S. patent application for a compact atomic clock based on Ramsey coherent population trapping targeting improved precision.
  • The technology is critical for aerospace and defense applications including satellite navigation, secure communications, and radar synchronization.
  • The company is advancing its strategy to commercialize quantum technology solutions, impacting sectors like aerospace, defense, finance, and communications infrastructure.

Tel Aviv, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Quantum X Labs Inc. (Nasdaq: QXL) (“QXL” or the “Company”), an advanced technologies company (formerly known as Viewbix Inc. (Nasdaq: VBIX)), announced today the filing of a U.S. patent application covering a novel compact atomic clock. By interrogating rubidium atoms with correlated optical fields the system suppresses existing atom clocks.

The technology covered by the patent application is based on a compact atomic clock architecture using Ramsey coherent population trapping.

High-precision atomic clocks are essential for the aerospace and defense industries for applications such as satellite navigation, secure communication networks, radar synchronization, autonomous platforms and other advanced defense technologies. Other industries that might need that level of timing synchronization by a quantum atomic clock are financial institutes and communication and other critical infrastructure facilities.

QXL’s strategy and approach aims to bring laboratory-grade performance into deployable and potentially commercial ready solutions across all its spectrum of quantum technologies portfolio.

About Quantum X Labs:

Quantum X Labs Inc. and its subsidiaries are focused on quantum technology, digital advertising and computing and enterprise artificial intelligence (AI) solutions. Quantum X Labs Ltd. is focused on developing and promoting quantum algorithms for the transportation, drug discovery and security segments as well as developing quantum- based GPS replacement and quantum atom accuracy solutions. Gix Media develops a variety of technological software solutions, which perform automation, optimization and monetization of internet campaigns, for the purposes of acquiring and routing internet user traffic to its customers. Metagramm is a developer of grammatical error correction software and offers tools for writing and reviewing, grammar, spelling, punctuation and style features, as well as translation and multilingual dictionaries, using artificial intelligence and machine learning technology.

For more information about Quantum X Labs, visit https://quantumxlabs.xyz/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the industries that may benefit from and the potential applications for high-precision atomic clocks and how its strategy and approach aims to bring laboratory-grade performance into deployable and potentially commercial ready solutions across all its spectrum of quantum technologies portfolio. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Because such statements deal with future events and are based on Quantum X Labs’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements could differ materially from those described in or implied by the statements in this press release.

The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed in any filings with the SEC. Except as otherwise required by law, Quantum X Labs undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Quantum X Labs is not responsible for the contents of third-party websites.

Investor Relations Contacts:

Michal Efraty
Investor Relations
michal@efraty.com 


Risks

  • Patent issuance is uncertain; the patent application may not result in an advantageous granted patent, affecting competitive positioning.
  • Reliance on forward-looking statements means actual results could materially differ, reflecting uncertainty in commercial adoption or technological challenges.
  • Market adoption risks exist as the technology targets specialized sectors, which may delay or limit revenue generation.

More from Press Releases

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 Jun 14, 2026 Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026 Jun 14, 2026 Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control Jun 14, 2026 Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026